The earnings call highlighted significant financial growth and successful product launches, with raised guidance indicating strong future performance. However, ongoing intellectual property litigation and potential regulatory challenges present concerns.

Company Guidance -

Q3 2025

During the Halozyme Second Quarter 2025 Financial and Operating Results Conference Call, several key metrics and updates were provided. The company reported a total revenue of $326 million for the quarter, marking a 41% increase from the same period last year, with royalty revenue growing by 65% year-over-year to $206 million. Adjusted EBITDA also saw a 65% increase to $226 million. The company raised its 2025 revenue guidance to $1.275 billion to $1.355 billion, reflecting a growth of 26% to 33% over 2024, and increased its royalty revenue guidance to $825 million to $860 million, representing a 44% to 51% growth. Halozyme completed a $250 million share repurchase and initiated an additional $250 million tranche under its $750 million plan. The company highlighted significant growth catalysts, including multiple new product approvals and expanded indications, with DARZALEX subcutaneous, Phesgo, and VYVGART Hytrulo being major growth drivers. The call also addressed ongoing IP litigation and the impact of regulatory changes, with confidence expressed in the durability and expansion of revenue streams.

Record-Breaking Revenue and Growth

Total revenue in Q2 2025 was $326 million, representing a 41% increase over the second quarter of the prior year. Royalty revenue grew 65% year-over-year to $206 million. Adjusted EBITDA increased 65% over the prior year second quarter to $226 million.

Raised Financial Guidance

Halozyme raised its 2025 financial guidance, now projecting total revenue of $1.275 billion to $1.355 billion, representing 26% to 33% growth over 2024. Full year royalty revenue guidance is increased to $825 million to $860 million, representing growth year-over-year of 44% to 51%.

Successful Product Launches and Approvals

New product approval for RYBREVANT subcutaneous in Europe and first-time approvals for Opdivo subcutaneous and VYVGART Hytrulo in Europe. The launch of OCREVUS ZUNOVO subcutaneous with ENHANZE is progressing well, with almost 7,000 patients treated globally.

Strong Performance of Blockbuster Products

DARZALEX second quarter revenue increased almost 22% to $3.5 billion. Phesgo's first half 2025 revenue was CHF 1.2 billion, reflecting a 55% year-over-year growth. VYVGART total sales increased 97% year-over-year in the second quarter to $949 million.

Share Repurchase Program

Completed the second $250 million share repurchase tranche of the $750 million plan and initiated the third $250 million share repurchase program.

Halozyme (HALO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HALO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	1.59 / -	1.27	―	―	―
Aug 05, 2025	2025 (Q2)	1.24 / 1.54	0.91	69.23% (+0.63)
May 06, 2025	2025 (Q1)	0.92 / 1.11	0.79	40.51% (+0.32)
Feb 18, 2025	2024 (Q4)	1.16 / 1.26	0.82	53.66% (+0.44)
Oct 31, 2024	2024 (Q3)	0.99 / 1.27	0.75	69.33% (+0.52)
Aug 06, 2024	2024 (Q2)	0.76 / 0.91	0.74	22.97% (+0.17)
May 07, 2024	2024 (Q1)	0.69 / 0.79	0.47	68.09% (+0.32)
Feb 20, 2024	2023 (Q4)	0.82 / 0.82	0.42	95.24% (+0.40)
Nov 06, 2023	2023 (Q3)	0.71 / 0.75	0.44	70.45% (+0.31)
Aug 08, 2023	2023 (Q2)	0.63 / 0.74	0.16	362.50% (+0.58)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HALO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$60.81	$62.32	+2.48%
May 06, 2025	$59.38	$70.14	+18.12%
Feb 18, 2025	$57.90	$57.77	-0.22%
Oct 31, 2024	$50.57	$57.15	+13.01%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Halozyme Therapeutics (HALO) report earnings?

Halozyme Therapeutics (HALO) is schdueled to report earning on Nov 10, 2025, After Close (Confirmed).

What is Halozyme Therapeutics (HALO) earnings time?

Halozyme Therapeutics (HALO) earnings time is at Nov 10, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is HALO EPS forecast?

HALO EPS forecast for the fiscal quarter 2025 (Q3) is 1.59.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing